– USA, CA – STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer, and marketer of implantable lenses for the eye, today announced the appointment of current Board Chair, Tom Frinzi, as President and CEO, effective January 1, 2023, replacing Caren Mason who will be retiring December 31, 2022.
The Board also appointed Steve Farrell, Chair of the Audit Committee, to serve as Lead Director, effective January 1, 2023.
About Thomas G. Frinzi
Mr. Frinzi was appointed to STAAR’s Board of Directors in June 2020 and has extensive experience in the ophthalmic and medical device industries at both large, well-established companies and innovative start-ups. He served as Worldwide President, Surgical for Johnson & Johnson’s Vision business, and previously as Senior Vice President of Abbott Laboratories and Abbott Medical Optics. Before Abbott, he served as President and CEO of WaveTec Vision, a developer of surgical systems for eye surgery. He previously held senior positions in commercial operations, business development, and sales and marketing at Bausch & Lomb Surgical, Refractec, and Chiron Vision.
“I am honored to be selected to lead STAAR as CEO and excited about our company’s future, especially our significant opportunity to launch EVO ICL in the United States,” said Mr. Frinzi. “Caren has set the company on extremely strong footing, and I will be highly focused on continuing our global growth and ensuring STAAR continues to lead the industry with innovative lens-based solutions that offer freedom from glasses and contact lenses. We have an incredibly strong team, a life-transforming solution for patients, and we are well positioned to continue to deliver for patients and the physicians who serve them, while also driving value for our shareholders.”
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures, and markets implantable lenses for the eye. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer Lens or “ICL,” which includes the EVO ICL product line. More than 2,000,000 ICLs have been sold to date and STAAR markets these lenses in over 75 countries.
For more information: https://staar.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.